RANBAXY

Fidelity International has informed the Exchange that Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries has acquired 258,626 shares aggregating to 0.07% of the total paid up capital of Ranbaxy Laboratories Ltd on February 01, 2006. The mode of acquisition is Open market and the shareholding of Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries after the said acquisition is 18,655,001 sh

Ranbaxy Laboratories Ltd has informed the Exchange regarding 22,70,652 shares held by Mr.Shivinder Mohan Singh, Director of the Company appointed on January 18, 2006.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated, January 24, 2006, titled, " Ranbaxy Launches Volix (VOGLIBOSE) for the treatment of Diabetes; Product introduced for the first time in India." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 18, 2006, titled "Brian Tempest promoted as Chief Mentor and Executive Vice Chairman Malvinder Mohan Singh takes charge as CEO and MD in smooth succession plan." The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 18, 2006, titled " Ranbaxy Year 2005 Global Sales at USD 1178 MN." The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on January 13, 2006 has allotted 32,003 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 372474193 Equity Shares of Rs.5 each aggregating Rs.1862370965.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 10, 2006, titled "Ranbaxy to co-market Ferring's Urology drug in India Treatment to benefit Paediatric and Geriatric Nocturia patients." The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the company dated January 02, 2006 titled "RANBAXY'S TOANSA PLANT RECEIVES NATIONAL AWARDS FOR EXCELLENCE IN WATER MANAGEMENT". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the company dated December 23, 2005 titled "Ranbaxy Laboratories Limited Announces an Agreement with Cephalon Regarding Settlement of Provigil� Patent Litigation; Parties Also Agree to Business Arrangements Related to Modafinil". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 17, 2005 titled "Ranbaxy to Appeal U.S. District Court Decision Upholding Pfizer Atorvastatin Patents". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 13, 2005 titled "Promising New Antimalarial Drug Demonstrates Significant Parasite Reduction in Patients". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 01, 2005 titled "Ranbaxy ready to help the U.S. Government to meet the Avian Flu Challenge". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 30, 2005 titled "Ranbaxy launches two new Anti-HIV products in India on World AIDS Day". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 28, 2005 titled "RANBAXY HONOURS INDIAN SCIENTISTS FOR OUTSTANDING RESEARCH CONTRIBUTIONS - RESEARCH AWARDS FOR THE YEAR 2004 PRESENTED". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has issued a press release dated November 23, 2005 titled "US Court of Appeals Uploads Preliminary Injunction Against Ranbaxy, Enjoining Company From Marketing Quinapril HCL Tablets - Case Moves to Trial in District Court". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company hosted an analyst meet on November 17, 2005 and the presentation made to the analysts shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release titled 'RANBAXY CONSOLIDATES RELATIONSHIP WITH JAPAN JV PARTNER NIPPON CHEMIPHAR; Equal partnership to reflect increased co-operation between both companies', being issued by the Company on November 11, 2005. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: corporates > latest announcements and on the extranet server (/common/corporateannouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 11, 2005 titled "US COURT DECISION PROVIDES CLARITY FOR LAUNCH OF RANBAXY'S CLARITHROMYCIN 500 MG EXTENDED RELEASE (ER) TABLETS UPON APPROVAL - Court rules in favour of Ranbaxy on two of three patents on Clarithromycin 1000 mg ER product". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release which is being issued by the Company dated November 10, 2005 titled 'Ranbaxy wins on atorvastatin process patent in Norway - will appeal Court ruling on intermediate compound patent.' The details of the press release shall be available on the nse website (http://www.nseindia.com) under: corporates > latest announcements and on the extranet server (/common/corporateannouncements).

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of Minutes of EGM of the Company held on October 21, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange of the result of the Postal Ballot conducted in regard to ordinary resolution under section 293 (1) (a) of the Companies Act,1956 authorising the BODs to divest/sell the Allied Businesses portfolio of the Company consisting of (1) Ranbaxy Fine Chemicals Limited (a wholly owned subsidiary), (2) Animal Health Care business and (3) Diagnostic Business. The details of the results of the postal ballot is as follows : (a) No. of valid ballots received in favour of the resolution-5326;(b)No. of votes cast in favour of Resolution- 160,559,936(99.94%);

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 03, 2005 titled " Ranbaxy granted permission to appeal U. K. High Court Judgement on patent relating to Atorvastatin ". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 31, 2005 titled "Ranbaxy Clarifies 180 day Exclusivities relating to Pravastatin 80mg and Simvastatin 80mg Tablets." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release being issued by the company dated October 27, 2005 titled, "Ranbaxy and Promotor group companies fortis healthcare, fortis securities & the escorts heart Institute & Research centre contribute Rs.1 crore in cash and essential medicines for Kashmir quake victims." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the shareholders of the Company at the EGM held on October 21, 2005 have approved the following. (1)Issuance of appropriate securities such as FCCBs and or/ GDRs and / or ADRs and / or any other securities/ instrument upto US Dollars 1500 million or equivalent. (2)Increase in Authorised share capital of the Company from Rs 200 crores to Rs 300 croers and consequential amendments in the Memorandum and Articles of Association. (3)Borrowing in excess of paid up share capital and free reserves of the Company upto Rs 5000 crores (4)Increase in

Ranbaxy Laboratories Ltd has informed the Exchange that the BODs at its meeting held on October 21, 2005 has approved payment of Interim Dividend of 50% (@ Rs.2.50 per share of par value of Rs.5 each) for the year ending December 31, 2005. Record date for determination of entitlement of the interim dividend has been fixed as November 05, 2005. Interim Dividend will be paid to the eligible shareholders on or before November 15, 2005.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the Company dated October 21, 2005, titled 'Ranbaxy Q3 Global Sales at USD 298 mn, up by 2% board approves interim dividend of 50% (Rs.2.50 per share)'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated October 19, 2005 titled, "Ranbaxy's Antimalarial Molecule Successfully Completes POC Phase II Studies", being issued by the company.' The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 12, 2005, titled "U.K. High Court rules in favour of Ranbaxy over one key atorvastatin patent, but says its product infringes another. Ranbaxy to appeal", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. V.K. Kaul, director has sold 15,000 shares of Ranbaxy Laboratories Ltd on October 07, 2005. The mode of sale is Market sale and the shareholding of Mr. V.K. Kaul after the said sale is 52,200 shares aggregating to 0.014% of the share capital of Ranbaxy Laboratories Ltd..

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 13, 2005, titled "Ranbaxy files suit against Barr Laboratories and Teva Pharmaceuticals USA", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. V.K. Kaul, director has sold 20,000 shares of Ranbaxy Laboratories Ltd on October 05, 2005. The mode of sale is Market sale and the shareholding of Mr. V.K. Kaul after the said sale is 67,200 shares aggregating to 0.018% of the share capital of Ranbaxy Laboratories Ltd.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 10, 2005, titled "Ranbaxy Gains Final Approval From USFDA To Manufacture and Market Gabapentin Capsules", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on October 10, 2005 has allotted 48,313 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 372442190 Equity Shares of Rs.5 each aggregating Rs.1862210950.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 07, 2005, titled "Ranbaxy Receives Final Approval From US FDA To Market Glimepiride Tablets", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of Notice of EGM of the company to be held on October 21, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 30, 2005, titled "Another Ranbaxy ARV Pre-Qualified by WHO". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the Company dated September 29, 2005, titled "Ranbaxy gains approval to market Pseudoephedrine Hydrochloride Extended-Release Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that a press release is being issued by the Company on September 27, 2005, titled "Ranbaxy to market Lupin's tuberculosis brands in severely affected West & North African markets." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated September 22, 2005, titled 'Ranbaxy launches in Canada - India's largest pharmaceutical company to bring high quality, affordable drugs to Canada.' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on September 20, 2005, titled "Ranbaxy receives approval from USFDA to Market Zidovudine tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated September 19, 2005, titled "RANBAXY RECEIVES TENTATIVE APPROVAL FROM USFDA TO MARKET TOLTERODINE TARTRATE TABLETS", being issued by the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated September 16, 2005, titled "RANBAXY RECEIVES FINAL APPROVAL FROM USFDA FOR GABAPENTIN TABLETS", being issued by the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated September 13, 2005, titled "RANBAXY LAUNCHES ITALIAN OPERATIONS; Now present in all top five pharmaceutical markets in Europe and 21 of 25 EU countries", being issued by the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the BODs at its meeting held on September 09, 2005, has approved the following subject to requisite approvals: 1) Listing of the Securities of the Company at a Stock Exchange in USA either through conversion of existing Global Depositary Receipts (GDRs) into American Depositary Receipts (ADRs) and/or through issuance of fresh security/instrument. 2) Raising of resources through appropriate securities such as FCCBs and/or GDRs and/or ADRs and/or any other appropriate security/instrument upto USD 1.5 Billion equivalent from time to time. 3

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated September 07, 2005, titled "Ranbaxy provides Relief Services to Victims of Hurricane Katrina". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 2, 2005, titled "RANBAXY TO FOCUS ON PHARMACEUTICALS BUSINESS; Reaches an understanding with potential buyers to divest its Allied Businesses", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 25, 2005, titled "RANBAXY RECEIVES PRESTIGIOUS SUPPLIER QUALITY AWARD FROM CARDINAL HEALTH; Second major supplier award for Ranbaxy this year following the earlier prestigious award from Wal-Mart", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on August 16,2005 titled " Ranbaxy opens third state of the art R&D facility on Gurgaon campus to focus on NCE discovery research". The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has announced on August 11, 2005, that the World Health Organisation (WHO), Geneva, has included the Company's seven Anti Retrovirals (ARVs) in its pre-qualification list. The details of the press release issued by the Company regarding the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).